The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Share News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,435.00
Bid: 1,454.00
Ask: 1,456.00
Change: -5.00 (-0.35%)
Spread: 2.00 (0.138%)
Open: 1,440.00
High: 1,474.00
Low: 1,435.00
Prev. Close: 1,440.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Housebuilders, Reckitt Help FTSE Ahead Of Powell

Thu, 11th Jul 2019 11:54

(Alliance News) - Sentiment on Thursday was boosted by dovish comments from US Federal Reserve Chair Jerome Powell on Wednesday, with markets now eyeing his second day in front of Congress. Housebuilders and Reckitt Benckiser were helping to support the FTSE 100, while Diploma was the top performer in the FTSE 250 in the wake of a bolt-on acquisition.The large-cap index was just 1.27 points higher at 7,531.96 Thursday midday. The mid-cap FTSE 250 index was up 36.68 points, or 0.2%, at 19,456.06, while the AIM All-Share was up 0.1% at 915.67.The Cboe UK 100 index was down 0.1% at 12,760.71. The Cboe UK 250 was flat at 17,346.69, while the Cboe UK Small Companies was up 0.3% at 11,271.46.In mainland Europe, the CAC 40 index in Paris and DAX 30 in Frankfurt were up 0.1% and down 0.1% respectively in afternoon trade.Wall Street is pointed to a positive open ahead of Powell's second day in front of Congress, with the Dow Jones and S&P 500 both seen up 0.3% and the Nasdaq called 0.4% higher."It's safe to say that investors were pleased with Jerome Powell's first day of testimony on Wednesday, with equity markets jumping on his dovish assessment," said Craig Erlam at Oanda. "Wednesday's message was clear, the data is softening - particularly on the inflation side - and downside risks are significant," said Erlam.Not shying away from market expectations of an interest rate cut later this month, Powell said many central bankers believed the case for lower rates "had strengthened" last month given rising "crosscurrents" in the economy.In his highly anticipated testimony to Congress, Powell repeatedly stressed the importance of keeping the US economy growing to ensure its benefits reach Americans left at the margins and said the central bank will deploy all its tools to support continued expansion."The second day of testimony is often largely a rerun of the first, from a monetary policy perspective. That won't stop traders keenly watching for signals though, particularly around the prospect for more cuts this year," the Oanda analyst commented. Powell will start the second day of his testimony at 1500 BST.Elsewhere in the economic calendar on Thursday, the European Central Bank releases accounts from its last monetary policy meeting at 1230 BST and US inflation readings are at 1330 BST.US CPI is seen easing to 1.6%, according to consensus cited by FXStreet, in June from 1.8% in May. On a monthly basis, however, consumer prices are seen rising 0.2% versus a 0.1% gain the previous month.France on Thursday became the first major economy to impose a tax on digital giants, with parliament passing the legislation in defiance of a probe ordered by President Donald Trump that could trigger reprisal tariffs.The new law aims at plugging a taxation gap that has seen some internet heavyweights paying next to nothing in countries where they make huge profits.The legislation - dubbed the GAFA tax - an acronym for Google, Apple Inc, Facebook Inc and Amazon.com Inc - was passed by a simple show of hands in the Senate upper house after previously being passed by the National Assembly lower chamber. In London, housebuilders were among the top performing stocks on Thursday."UK homebuilders continue to find favour after Barratt's update yesterday. The sector has received a boost after a period of weakness in construction, although those investors moving in now will have to be mindful of the potential disruptions arising from a no-deal Brexit," said Chris Beauchamp, chief market analyst at IG. Barratt Developments was the best performer in the FTSE 100, up 3.7%, while Taylor Wimpey advanced 1.5% and Berkeley Group up 1.2%.Another blue-chip riser was Reckitt Benckiser, up 2.4% after agreeing to pay USD1.4 billion to settle a probe into former pharmaceuticals arm Indivior.The FTSE 100-listed consumer goods firm will pay up to USD1.4 billion to fully resolve all federal investigations into Reckitt in connection with Indivior's indictment and claims relating to state Medicaid programs for those states choosing to participate in the settlement.In September 2016, 35 US states and the District of Columbia filed a civil complaint against Indivior in relation to its ongoing legal privilege dispute with the US Federal Trade Commission. Indivior was wholly demerged from Reckitt, which makes Dettol disinfectant and Strepsils lozenges, in 2014. Suboxone is an opioid used to treat opioid addiction, acute pain, and chronic pain.Separately, Indivior shot up 26% after upgrading its guidance following a stronger than anticipated first half. Indivior - which did not mention the Reckitt announcement in its own on Thursday - now expects net revenue in a range of USD670 million to USD720 million, a sharp increase from previous forecasts of USD525 million to USD575 million. Net income is expected between USD80 million to USD130 million. Prior to this, the company had anticipated anything from a loss of USD40 million to income of USD10 million. The primary driver has been a market share outperformance from Suboxone Film, the company explained. FTSE 250-listed technical products and services firm Diploma helped to support the index after agreeing to buy a gasket and fluid-sealing products maker.Virginia Sealing Products specialises in customers who process and transport hazardous materials but also operates in markets such as power generation, pulp & paper, and marine. Diploma is paying GBP56.0 million in cash upfront, but it may also pay a further GBP8.0 million if VSP meets various operating profit targets. Elsewhere on the Main Market, McBride sank 12% on a profit warning.Trading in the second half of McBride's year ended June was "marginally" weaker than expected, the firm said, with revenue down 1.7% on the first half of the year. France and the UK were especially weak.This weakness has continued into McBride's new financial year, "mostly" due to slow demand in a number of markets as well as the effect of some lost contracts due to price increases. As a result, earnings in the year ending June 2020 are set to fall on McBride's recently ended year.

More News
16 Feb 2022 07:49

LONDON MARKET PRE-OPEN: Franchise Brands buys fellow AIM firm Filta

(Alliance News) - Stock prices in London are seen opening slightly higher on Wednesday, adding to strong gains on Tuesday, as tensions on the Russia-Ukraine border appear to have eased.

Read more
16 Feb 2022 07:05

Indivior considers US listing after returning to profit

(Sharecast News) - Indivior said it was considering a US listing for its shares as the drugs company swung to an annual profit and predicted strong growth for its Sublocade opioid.

Read more
9 Feb 2022 16:02

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
28 Jan 2022 16:22

UPDATE: Indivior notes robust results for treatment in fentanyl trial

UPDATE: Indivior notes robust results for treatment in fentanyl trial

Read more
28 Jan 2022 14:53

CORRECT: Indivior notes results for painkiller in fentanyl trial

CORRECT: Indivior notes results for painkiller in fentanyl trial

Read more
28 Jan 2022 09:02

Indivior's painkiller demonstrates positive interaction with fentanyl

Indivior's painkiller demonstrates positive interaction with fentanyl

Read more
28 Jan 2022 07:55

Indivior welcomes results from buprenorphine-fentanyl interaction study

(Sharecast News) - Pharmaceutical company Indivior hailed the results of a study aimed at assessing the ability of its buprenorphine asset to reduce respiratory depression and apnea associated with the synthetic opioid fentanyl.

Read more
19 Nov 2021 14:56

EXECUTIVE CHANGES: Dechra Pharmaceuticals picks Alison Platt as chair

EXECUTIVE CHANGES: Dechra Pharmaceuticals picks Alison Platt as chair

Read more
10 Nov 2021 12:28

LONDON MARKET MIDDAY: Stocks rise as investors eye US inflation data

LONDON MARKET MIDDAY: Stocks rise as investors eye US inflation data

Read more
10 Nov 2021 10:12

IN BRIEF: Scopia sells 2.8% stake in Indivior for GBP50 million

IN BRIEF: Scopia sells 2.8% stake in Indivior for GBP50 million

Read more
10 Nov 2021 08:07

Indivior slumps as Scopia Capital sells 20m shares

(Sharecast News) - Indivior was under the cosh on Wednesday after US alternative asset management firm Scopia Capital sold 20m shares in the opioid addiction treatment maker in a placing.

Read more
1 Nov 2021 09:38

LONDON BROKER RATINGS: Upgrades for Lloyds Banking and NatWest

LONDON BROKER RATINGS: Upgrades for Lloyds Banking and NatWest

Read more
28 Oct 2021 13:23

Indivior lifts 2021 revenue guidance amid strong Sublocade sales

Indivior lifts 2021 revenue guidance amid strong Sublocade sales

Read more
28 Oct 2021 12:17

Indivior lifts FY guidance as Q3 profits, revenue jump

(Sharecast News) - Indivior lifted its full-year guidance on Thursday as it reported a rise in third-quarter revenue and profit.

Read more
24 Oct 2021 17:12

Sunday share tips: Light Science Technologies, Indivior

(Sharecast News) - The Financial Mail on Sunday's Midas column told readers to buy shares of Light Science Technologies, pointing out the benefits of the company's technology for health, climate and the UK more economy.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.